Nanjing King-Friend Biochemical Pharmaceutical (SHA:603707) subsidiary Emerge Bioscience obtained U.S. Food and Drug Administration approval to manufacture adalimumab injection at Kingfriend's manufacturing facility.
The biosimilar, sold under the brand YUSIMRY, was originally approved for nine indications including rheumatoid arthritis, Crohn's disease and psoriasis, according to a Wednesday filing with the Shanghai bourse.
Shares of the pharmaceutical company declined 5% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.